Monday, June 17, 2024
HomeHealth ConditionsCancerA new compound to treat prostate cancer

A new compound to treat prostate cancer

Scientists develop a new compound to block the interaction of proteins involved in driving drug-resistant prostate cancer.

Prostate cancer occurs when abnormal cells develop in the prostate. It is the second leading cause of cancer death in American men. According to the American Cancer Society, there will be over 161,000 new cases, causing about 26,700 deaths in 2018. There is no known cause for prostate cancer, but it has long been linked to older age, family history, obesity, and exposure to certain chemicals.

Prostate cancer occurs most often in men older than 65. In the early stages, there may be no symptoms. In the late stages, symptoms may include trouble urinating, decreased force in the stream of urine, blood in semen, sexual problems, and pain.

Current androgen deprivation therapy shows limited success

The androgen receptor plays a central role in the initiation and growth of prostate cancer. Androgen deprivation therapy has been considered a gold standard of treatment. This new generation of antiandrogen drugs such as Xtandi and Zytiga have shown an improvement of life expectancy of a few months. However, a large number of patients treated with anti-androgens will develop resistance and continued disease progression, a state known as metastatic castration-resistant prostate cancer.

New compound to interfere with the growth of therapy-resistant prostate cancer

In a recent study published in Nature Communications, a joint research team from New York University in the United States developed a new compound that blocks the protein interaction involved in driving drug-resistant prostate cancer. Unlike the typical androgen deprivation therapy which targets the androgen receptor, this new compound is designed to block the cancer growth by interfering the protein-protein interactions. This helps to prevent proteins turn on genes that make cells multiply.

Meaningful results of suppressing cancer cell growth

The scientists continued to investigate the blocking effectiveness of the compound using prostate cancer cell lines. Compared with the untreated cancer cells, the new compound was capable of reducing the proliferation of prostate cancer cells by 95 % over 22 days. The scientists also demonstrated that their compound could block beta-catenin signals in a live zebrafish without harming zebrafish embryo development.

This exciting study opens new doors to reshape future therapy for prostate cancer. Further animal testing on rodents will be important to determine the therapeutic potential of the new compound.

Written by Man-tik Choy, Ph.D.

Reference: Schneider J.A. et al. Design of Peptoid-peptide Macrocycles to Inhibit the β-catenin TCF Interaction in Prostate Cancer. Nature Communications, 2018;9:4396. DOI: 10.1038/s41467-018-06845-3.

Man-tik Choy PhD
Man-tik Choy PhD
Man-Tik has a Ph.D. in Material Science and Engineering from the Hong Kong Polytechnic University. His research focuses on pharmaceutical sciences, biomaterial design and development, and advanced manufacturing technologies. Man-Tik has developed a strong interest in knowledge discovery and sharing through his practical training in different joint research projects. He is excited to contribute to Medical News Bulletin and help the public to understand science more effectively. In his free time, Man-Tik enjoys reading novels and painting.
RELATED ARTICLES

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest News and Articles

SUBSCRIBE TO OUR NEWSLETTERS

Stay Connected
10,288FansLike
820FollowersFollow
249FollowersFollow
2,787FollowersFollow

Article of the month

Vitamin D as an Anti Colorectal Cancer Agent in 2024 – a Review of the Evidence

Vitamin D has a protective effect against colorectal cancer, but it is patient and population dependent.According to the WHO, colorectal cancer (CRC) is the...

Joke Of The Day – June 18

Doctors can never wish anything for Christmas because Santa can't read their writing…

ADVERTISE WITH US

error: Content is read-only and copy-protected.